Physician profile
Anuj Sharma
NPI 1881673507
$5,360.46
in general payments reported to CMS, 2019-2025
35 companies · $1,014 in 2025
The $1,014 reported for 2025 was more than what 87% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $358 · 2021: $797 · 2022: $757 · 2023: $949 · 2024: $1,018 · 2025: $1,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,980.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,220.19 | 2021-2025 | Qulipta, Ubrelvy |
| Pfizer INC. | $988.37 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $799.58 | 2019-2025 | Xtampza, Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $573.22 | 2019-2025 | Relistor |
| Biohaven Pharmaceutical Holding Company LTD. | $251.35 | 2022 | |
| Protega Pharmaceutials INC | $229.80 | 2023-2025 | Roxybond |
| Stryker Corporation | $124.78 | 2021 | |
| Acelrx Pharmaceuticals, INC. | $119.38 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $116.13 | 2021 | |
| Idorsia Pharmaceuticals US INC | $91.25 | 2022-2024 | Quviviq |
| Valinor Pharma, LLC | $85.75 | 2023-2025 | Movantik |
| Novartis Pharmaceuticals Corporation | $66.51 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $64.98 | 2023-2024 | Rexulti |
| Boston Scientific Corporation | $57.88 | 2019-2020 | |
| Tonix Medicines, INC. | $52.91 | 2025 | Tonmya |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $51.24 | 2021-2022 | |
| Grt US Holding, INC. | $45.02 | 2022 | |
| Lundbeck LLC | $38.84 | 2024 | Vyepti |
| Scilex Pharmaceuticals INC. | $34.24 | 2022-2025 | |
| Lilly USA, LLC | $32.37 | 2019 | |
| Arbor Pharmaceuticals, INC. | $31.84 | 2019-2021 | |
| Hikma Pharmaceuticals USA | $31.62 | 2022 | |
| Allergan, INC. | $30.06 | 2020 | |
| Pacira Therapeutics, INC. | $25.35 | 2019 | |
| Daiichi Sankyo INC. | $23.30 | 2019 | |
| Alexion Pharmaceuticals, INC. | $23.20 | 2019 | |
| Amneal Pharmaceuticals LLC | $21.50 | 2023 | Lyvispah |
| Redhill Biopharma INC. | $18.77 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $18.52 | 2025 | |
| Neurometrix INC | $18.33 | 2023 | |
| Azurity Pharmaceuticals, INC. | $18.08 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $16.04 | 2023 | Seglentis |
| Kaleo, INC. | $15.50 | 2019 | |
| Bioventus LLC | $12.38 | 2019 | |
| Supernus Pharmaceuticals, INC. | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anuj Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.